Download MedDRA Term Groupings: Use in clinical, drug safety and regulatory

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts

Patient safety wikipedia , lookup

Women's medicine in antiquity wikipedia , lookup

Medical image computing wikipedia , lookup

Medical ethics wikipedia , lookup

Transcript
MedDRA Term Groupings:
Use in clinical, drug safety and regulatory
departments
INTRODUCTION
Christina Winter
GlaxoSmithKline
MedDRA hierarchy
• MedDRA hierarchy:
– SOCs, HLGTs, HLTs and PTs
gather terms below them so could
be considered “groupings”
– LLT is the lowest level and there
are no official MedDRA terms
below LLT
– However some browsers use
synonyms behind the scenes to
aid retrieval (e.g. If synonyms are
used, searching for “hepatic
necrosis” will also retrieve LLT
Liver necrosis.)
Synonym Lists
• Synonym lists
– Some users maintain synonym lists
within their own systems
– linked to LLTs
– aid consistency of coding
– aid the autoencoder function
– need maintenance for each
MedDRA version
Paediatric / Gender Lists
MSSO maintains
• Paediatric adverse event list
• Gender adverse event list
– Intended to improve data quality of adverse event reporting
– May be used in conjunction with database fields
– Unlike SMQs, these lists are not intended to identify a medical condition
or area of interest.
Standardised MedDRA Queries
Standardised MedDRA Queries (SMQs)
– Produced by CIOMS and MSSO collaboration; tested on regulatory and
company databases prior to release
– Maintained by MSSO; guidance available in
– Introductory guide for SMQs
– Data Retrieval and Presentation: Points to Consider
– Intended to identify a medical condition or area of interest
– Recommended by regulatory authorities as first strategy for searching
safety data
– May be applied to signal detection
– Medical review of data retrieved is necessary
– Quality of data retrieved is highly dependent on accurate coding
In-house MedDRA groupings (1)
•
•
•
•
Created and maintained by individual users/companies
Used globally or tailored for product
Generally topics not covered by SMQs
Constructed with any level of MedDRA hierarchy, sub-SMQs, modified
SMQs etc
– “Home grown queries”
– In-house searches (MedDRA terms with/without database fields)
– “Drug/Event pairs”
– Refer to group(s) of terms reflecting condition(s) of interest for specified drug
– Incoming data: alert for expedited manual review
– If term coded, alert case handler that special follow up questionnaire is needed
In-house MedDRA groupings (2)
– Grouping terms for labelling
– Narrow list of search terms to aggregate safety data to create labelling
(regulatory use)
– Narrow list of terms to interpret labelling
– E.g. “Myocardial infarction” in product label:
PTs Myocardial infarction, Acute myocardial infarction, Post procedural
myocardial infarction, Silent myocardial infarction considered “listed/expected”
– Designated Medical Events (DMEs)
– Grouping of terms reflecting serious medical conditions that are
– typically due to drug
– lead to benefit/risk review
– DME medical concepts include Stevens Johnson syndrome, Aplastic
anaemia, Seizure
EMA’s Important Medical Events
Topic for later presentation at this meeting
Thank you
E<EMA Important Medical Events list
Identification of serious events in Drug Safety
Christina Winter
GlaxoSmithKline
EMA’s Important Medical Events (IME)
• EMA’s Eudravigilance expert working group created and maintain
IME list
• IME List (PTs) and inclusion/exclusion criteria on EMA Eudravigilance
website
http://eudravigilance.ema.europa.eu/human/textforIME.asp
• Very large list (>7,900 PTs in v19.0)
• Intended as aid to select events of higher priority for
pharmacovigilance
Use by Drug Safety Departments
• Post marketing reports require expedited reporting if they are serious
• Serious includes regulatory serious criteria and “medically serious” if
none of the regulatory serious criteria applied to the case
• Post marketing reports from any source; reporter may not be
healthcare professional
• Medically serious judgement varied between drug safety physicians
• For consistency of “medically serious”, drug safety departments may
apply a medically serious list in the database.
• In addition to expedited reporting, list may be applied to periodic
reports (separating non-serious from serious)
Use by Drug Safety Departments
• GSK initially maintained its own list
• High maintenance effort
• Always of interest in audits by regulatory agencies (who may have different
opinions on terms selected)
• GSK now uses the entire IME list
• Adds a few terms that are specifically required for vaccine expedited reporting
(e.g. Vaccination failure)
• Simpler (only need to maintain vaccine list)
• Less likely to have queries in regulatory audits
• Other companies remove terms from the IME list
• Requires maintenance
Thank you
EMA Important Medical Event list for the identification
of serious adverse events in clinical studies
Carol-Ann Wilson
MedDRA User Group Meeting Hamburg April 5, 2016
Scope of IME list
• A serious adverse event is any untoward medical occurrence in clinical studies
that:
1. Results in death
2. Is life-threatening
3. Requires in-patient hospitalization or prolongation of existing hospitalization
4. Results in persistent or significant disability or incapacity
5. Is a congenital anomaly or birth defect
6. Is another medically important serious event as judged by the investigator, i.e.
may not be immediately life-threatening or result in death or hospitalization
but may jeopardize the patient or may require intervention to prevent one of
the other outcomes listed in the definitions above
• The IME list includes MedDRA PTs that represent these outcomes. It is quite
broad because it also intends to cover the last outcome category
Page 2
MedDRA User Group meeting• 5 April 2016
Use of IME list in clinical studies
• The IME list is provided and maintained by the EMA and was created to facilitate
the seriousness classification of suspected adverse reactions and to support
aggregated data analysis and case assessment in day to day pharmacovigilance
activities of stakeholders in the EU
• Consistent classification of seriousness of adverse events/reactions is
difficult to achieve when relying on Investigator assessment alone
• It has a guidance purpose only and is not a mandatory requirement for
seriousness assessment and regulatory reporting. Thus, organizations have the
option to use it for their purposes depending on their individual needs
• Within Bayer, the IME list is used in clinical trials to support the medical review
process in terms of consistency of the seriousness definition of adverse events
Page 3
MedDRA User Group meeting• 5 April 2016
Use of IME list in clinical studies
Process (1)
• The IME list can be adapted on a project and study level by excluding PTs that
are already covered by e.g. study inclusion criteria or study endpoints
• The IME list with justification for exclusion of specific PTs is attached to the
Medical Review Plan and has to be approved by the responsible medical
experts in Clinical and Drug Safety
• The Study Data Manager regularly runs an IME based macro on non-serious
AEs and provides listings of potentially serious AEs that were identified by the
(adapted) IME list
• An additional tab identifies excluded PTs in the study
• A complementary medical history listing will provide information about medical
history findings that have the same MedDRA PT assignment as the listed AEs
for the relevant patients
• Another tab lists all documented AEs for the respective patients with grading/
severity information
Page 4
MedDRA User Group meeting• 5 April 2016
Process: Use of IME list in clinical
studies (2)
• The Study Medical Expert regularly performs the medical review of the listing of
potentially serious AEs
• After each review, queries to the Investigator are raised for the upgrading of
non-serious AEs to serious AEs, where medically appropriate
• A listing with the acceptable non-serious adverse events is sent back to the
Study Data Manager
• Any further created report will be up-to-date concerning latest comments by
Study Medical Expert
• The creation of the IME derived listing will be cumulative. New records will be
highlighted and AEs classified as serious will be removed
• The Study Medical Expert evaluates the Investigator’s response and either
closes the query or posts a re-query
• If the site disagrees with the upgrading, the adverse event will remain
classified as non-serious
Page 5
MedDRA User Group meeting• 5 April 2016
Process: Use of IME list in clinical
studies (3)
• New versions of the IME list are implemented in each study when a new
MedDRA version is released into production
• All processes will be run for all subjects as described before, based on the
new version of the IME list
• If a query was posted before implementation of the new version of the IME list,
the query will not be withdrawn
• If the Investigator has classified an AE as serious based on a previous version
of the IME list but the PT has been removed from its new version, the previous
classification will not be re-queried or revised
• The process is iterative until study completion and all queries are resolved
• Study Medical Expert confirms the final status of the IME derived listing as part of
the confirmation of completion of medical review
• Any non-serious AE that is upgraded to an SAE near data base closure will
require SAE reconciliation macros to be re-run
Page 6
MedDRA User Group meeting• 5 April 2016
Process: Use of IME list in clinical
studies (4)
Subject
Number
Investigator verbatim
180060002 LIVER INJURY
180090016 HEART FAILURE WORSENING
Real
No.
(Diff.
since
EudraVigilance Important
09FEB
Medical Event (IME) Term
2016)
(MedDRA PT)
1(0)
Liver Injury
1(0)
Cardiac Failure
To
Clinical
Trial
be
Trial
unit
queri
Comments
Number Country number ed
Queries
15626
POLAND 18006
Y
It was non serious adverse event
15626
POLAND 18009
Y
this is not serious AE
EPIDERMOID CARCINOMARIGHT
300030003 CHEST
1(0)
Squamous Cell Carcinoma Of Skin 15626
400010002 BCC LEFT INFRACLAVICULAR
1(+1)
Basal Cell Carcinoma
15626
420030004 THORACIC TRAUMA
1(0)
Chest Injury
15626
560040002 GASTRIC ULCER
1(0)
Gastric Ulcer
15626
CRUSHING INJURY OF THE
FIFTH FINGER OF THE RIGHT
820110005 HAND
890040004 HYPERTENSION CRISIS
1(0)
1(+1)
710050010 UPPER GI BLEEDING
400040004 PULMONARY ASPERGILLOSIS
Page 7
MedDRA User Group meeting• 5 April 2016
NETHERL
ANDS
AUSTRALI
A
PORTUGA
L
SOUTH
KOREA
Y
no serious, It was operable and
no further treatment is necessary
42003
Y
REPLY is PENDING
56004
Y
confirmed not serious
"""We confirm that the event was
not serious. It was an accidental
injury of the finger which did not
require hospitalization."
30003
40001
15626
15626
ROMANIA 82011
SERBIA
89004
Y
1(0)
Limb Crushing Injury
Hypertensive Crisis
Upper Gastrointestinal
Haemorrhage
15626
Y
1(0)
Bronchopulmonary Aspergillosis
15626
THAILAND 71005
AUSTRALI
A
40004
Y
Confirmed this event is not SAE.
Further investigator review
determined to be Not Serious
Thank you!
Servier
Sabine Bayle
Medical Data Quality and Tools Project Manager
Claudine Gontier
Medical Data Coding Project Manager
Topic 1: Ontological thesaurus
Topic 2: How do we use
MedDRA to carry out medical
data cleaning
Topic 1
Ontological thesaurus
Guidelines
Semiologic thesaurus
Clinical Knowledge
For human
consultation
Semiological Ontology
Artificial intelligence
For IT purposes
MedDRA Terms selection-Points to consider
for multiple diagnosis
Inspection findings
Major findings
regarding 5 adverse
events (on > 17000 AEs)
where a symptom was
not coded
Adverse events
in our Clinical database
 330 000 AEs in our clinical trials
3 300 PT used in these studies
756 PT corresponding to 80% of AEs
490 PT diagnosis
90 medical concepts
Semiologic thesaurus
10 medical areas represented
including 3 principal ones:
-Cardiovascular
-Psychiatry
-Neurology
90 Medical Concepts (diagnosis )
2248 characteristic signs
and symptoms (PT)
Semiologic Thesaurus
Today we have 90 medical conditions with characteristic
signs/symptoms NOT to be coded in addition to the medical
condition if reported as part of a verbatim by investigator
Medical condition Not to be coded in addition to the corresponding medical condition
Bradycardia
• Heart rate decreased
• Dizziness
• Thoracic discomfort/pain
• Asthenia (weakness), fatigue, malaise
From Thesaurus to Ontology
Creation of an Ontology  structured database with
links between Diagnosis PT and their main Signs and
Symptoms PT
Syncope
exertional
Aortic
valve
stenosis
Dyspnoea
on effort
Aortic valve
calcification
Left
ventricular
hypertrophy
Angina on
exercise
Palpitation
Systolic
murmur
9
Text Mining reminder
Medical Concept1, MC2,
MC3, MC4
PT1, PT2, PT3, PT4
Reported Terms
Split Coded Terms by Text Mining
Reported Terms
ATRIAL FIBRILATION / DISPNEA,
PALPITATION / WHEN TACHIACARDIA
(ATRIAL FIBRILATION ) PERSISTED, A
PATIENT FELT PALPITATION SO HE CAME TO
THE HOSPITAL
Split coded Terms by Text Mining
PTcod1 : ATRIAL FIBRILLATION
PTcod2 : DYSPNOEA
PTcod3 : PALPITATIONS
PTcod4 : TACHYCARDIA
Each medical concept of a reported adverse event is coded 
Splitting methodology (not recommended  !)
Text mining to Ontology
Medical Concept1, MC2,
MC3, MC4
PT1, PT2, PT3, PT4
Ontology
Reported Terms
Split Coded Terms by Text Mining
PT1, PT4
Recommended 
Diagnosis: Bradycardia
S&S: blurred vision and dizziness
Today
Tomorrow
Manual selection of terms to be
coded with help of thesaurus
Identification of medical concepts
(Text mining)
Translation of all detected terms
(Medical ontology)
Selection of terms to be coded
CODING
Bradycardia/ 10006093
Blurred vision / 10005886
Semiological ontology:
« MetaDRA »
How did we fill in the « MetaDRA » ?
Translated the 90 medical conditions from the semiologic
thesaurus into MedDRA terms to supply the MetaDRA database.
The MetaDRA interface
 A dropdown list of medical conditions is available:
The MetaDRA interface
 Medical concept:
The Diagnosis LLT are the
codes that are considered
as medical concepts.
Any characteristic sign or
symptom reported in a
verbatim would not be
coded in addition
Topic 2
How do we use MedDRA in our daily work
in addition to our coding activities?
Medical data cleaning
Medical data cleaning
The medical data cleaning is set up by our department in order to
detect potential medical inconsistencies in the clinical trials
database using automated and manual checks.
Medical data cleaning
Checks developed for:
•AEs, medical and surgical histories,
•Previous and concomitant medications,
•biological data and vital signs.
And run on MedDRA lists of codes.
Medical data cleaning
Patient
Patient
number Country Center identification Type of control
1646
40
402
Liver disorder
Liver disorder
Coding
process
40040201646 AE_X
Discrepancy message
Detection
date
PT ‘Liver disorder' is a vague PT and has to be
checked
06NOV2015
Satuts
Comments
Medical data cleaning
Patient
number Country Center
1717
112
4005
Type of
control
MR_AE_04_S
TD
Event number
E01
Discrepancy message
The event is not related to study drug but the
action taken regarding study drug is Dose
increased
Detection
date
06NOV2015
Satuts
Comments
Medical data cleaning
Type 2 diabetes
mellitus
Drugs used in
diabetes
Patient
Patient
Disease
number identification Type of control verbatim
1717
Type 2
400501717 MR_MH_05_STD diabetes
PT code
Discrepancy message
Type 2
diabetes This event is reported as treated but there
mellitus is no corresponding treatment reported
Detection
date
06NOV2015
Satuts
Comments
Review and handling of discrepancies
NEW Discrepancy
Inconsistency
Inconsistency
‘Not real’
‘Real’
Change
code
List of codes
Not correct
or
DB error
No query
needed
No action
Needed
Resolved
internally
+ comments
No query
Wait
+ comments
Query
already sent
+ open
Query
already answered
Explanation
No action
Needed
+ comments
No query
New
Wait
Check if
new query needed
Sent
+/- Sent
Query Sent
22
Medical validation cleaning Example :
Coherence between hematology and MH pages
For hemoglobin values below 90g/l in eCRF. Check presence of
medical history using MedDRA list of codes
Discrepancy message:
« The HEMOGLOBIN(37 g/L) is less than 90 g/L but no corresponding
medical history is reported »
Step1: Verify if medical history reported in eCRF  No MH
Step2: Issue a query in eCRF
Step3: Change status of discrepancy once query issued
Medical validation cleaning Example :
Coherence between hematology and MH pages
Step 4: Query answer reporting error. Data corrected in
eCRF by investigator
Step5: discrepancy closed automatically
PATIENT
IDENTIFICA
STUDY COUNTRY CENTRE
TION
10
76
525
4198
VISIT
M000
BIOP
HGB
STATUSME
COMMENTS
D
PANEL
The HEMOGLOBIN (37g/L) is
less than 90g/L but no
corresponding medical history
is reported
CLOSED
HEM1VAL
COMSTAT
Q sent
How we deal with
Important Medical Events (IME)
EMA provides a list of MedDRA codes (Preferred Terms) called
Important Medical Events
Non serious Adverse events coded with a PT from the IME list have
to be reviewed according to predefined seriousness upgrade rules.
Any AE that is upgraded is transferred to the pharmacovigilance for
declaration purposes
IME Process
AE3
AE2
AE1
AE1
PV DB
Upgrade rules criteria
IME
PT ?
No
Yes
medical
review
Criteria
fulfilled
Missing
data
Criteria
not
fulfilled
Tripartite
meeting
interface
Yes
Wait
No
Clinical Data Base
Thank you for
your attention!